Related references
Note: Only part of the references are listed.Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
John H. Strickler et al.
CLINICAL CANCER RESEARCH (2021)
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer
Bela Goyal et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Identification of an Immune-Related LncRNA Signature in Gastric Cancer to Predict Survival and Response to Immune Checkpoint Inhibitors
Zuoyou Ding et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma
Xueying Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
LncRNA DRAIR is a novel prognostic and diagnostic biomarker for gastric cancer
Tian Jin
MAMMALIAN GENOME (2021)
Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
Tapan Behl et al.
CANCERS (2021)
A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma
Jiahang Song et al.
BIOENGINEERED (2021)
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study
Solmaz Sahebjam et al.
NEURO-ONCOLOGY (2021)
Immunotherapeutic approaches for small-cell lung cancer
Wade T. Iams et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC)
Wen Jiang et al.
CANCER MEDICINE (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li et al.
NUCLEIC ACIDS RESEARCH (2020)
LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1
Ming Zhang et al.
CELL PROLIFERATION (2020)
Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma
Xuechao Wu et al.
ONCOTARGETS AND THERAPY (2020)
Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer
Yucai Wu et al.
Aging-US (2020)
Immune microenvironment composition in non-small cell lung cancer and its association with survival
Menno Tamminga et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
Francesca Finotello et al.
GENOME MEDICINE (2019)
Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
Gregor Sturm et al.
BIOINFORMATICS (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers
Lirong Peng et al.
CANCER MEDICINE (2019)
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2019)
What did we learn from CTLA-4 insufficiency on the human immune system?
Noriko Mitsuiki et al.
IMMUNOLOGICAL REVIEWS (2019)
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target
Jun Wei et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
Checkpoint inhibitors in breast cancer - Current status
Anne Polk et al.
CANCER TREATMENT REVIEWS (2018)
LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO
Xinhong Pei et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Cornerstones of CRISPR-Cas in drug discovery and therapy
Christof Fellmann et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
Zhixin Sheng et al.
ONCOTARGET (2017)
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Anna C. Filley et al.
ONCOTARGET (2017)
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Julien Racle et al.
ELIFE (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Yoshinaga Okugawa et al.
GASTROENTEROLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis
Xi Feng et al.
ONCOTARGET (2015)
Treatment Considerations for MGMT-Unmethylated Glioblastoma
Jennie W. Taylor et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2015)
Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling
Feng Hu et al.
NEURO-ONCOLOGY (2015)
Molecular characterization of long-term survivors of glioblastoma using genome-and transcriptome-wide profiling
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
The brain tumor microenvironment (vol 59, pg 1169, 2011)
Nikki A. Charles et al.
GLIA (2012)
Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas
Jane R. Engler et al.
PLOS ONE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
